Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects

Urology

Volumn 67, Issue 6, 2006, Pages 1199-1204

  Giuliano, François ^a   Kaplan, Steven A ^b   Cabanis, Marie Josée ^c   Astruc, Béatrice ^d  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c SANOFI   (France)

^d Biotrial SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; TADALAFIL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ERECTILE DYSFUNCTION; HEMODYNAMICS; HUMAN; MALE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; CARBOLINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; QUINAZOLINES; REFERENCE VALUES;

EID: 33744513290     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.01.001     Document Type: Article

References (25)

1. Cockett A.T.K., Aso Y., Denis L., et al. Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH). In: Cockett A.T.K., Khoury A.S., Aso Y., et al. (Eds). Recommendations of the International Consensus Committee, Paris: June 1993 (1993), Scientific Communications International, Jersey 553-672
2. Roehrborn C.G., Bartsch G., Kirby R., et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia. a comparative, international overview. Urology 58 (2001) 642-650
3. Gee W.F., Holtgrewe H.L., Albertsen P.C., et al. Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J Urol 154 (1995) 205-206
4. Narayan P., and Tewari A. Overview of alpha-blocker therapy for benign prostatic hyperplasia. Urology 51 (1998) 38-45
5. Andersson K.E. Alpha-blockers therapy in benign prostatic hyperplasia. 3. Uroselectivity. In: Cockett A.T.K., Khoury A.S., Aso Y., et al. (Eds). The Third International Consultation on Benign Prostatic Hyperplasia (BPH), Monaco (1996), Scientific Communications International, Jersey 541-542
6. van Kerrebroeck P., Jardin A., Laval K.U., et al., ALFORTI Study Group. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 37 (2000) 306-313
7. Roehrborn C.G. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia. a randomized, placebo-controlled trial. Urology 58 (2001) 953-959
8. Roehrborn C.G., van Kerrebroeck P., and Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia. a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92 (2003) 257-261
9. Moncada I. LUTS. a risk factor for sexual dysfunction in the BPH patient. Eur Urol 2 (2003) 3-8
10. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction. the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 44 (2003) 637-649
11. Nicolosi A., Moreira Jr. E.D., Shirai M., et al. Epidemiology of erectile dysfunction in four countries. cross-national study of the prevalence and correlates of erectile dysfunction. Urology 61 (2003) 201-206
12. Boyle P., Robertson C., Mazzetta C., et al., UrEpik Study Group. The association between lower urinary tract symptoms and erectile dysfunction in four centres. the UrEpik study. BJU Int 92 (2003) 719-725
13. Braun M.H., Sommer F., Haupt G., et al. Lower urinary tract symptoms and erectile dysfunction. co-morbidity or typical "aging male" symptoms? Results of the "Cologne Male Survey.". Eur Urol 44 (2003) 588-594
14. Lue T., Guiliano F., Montorsi F., et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 1 (2004) 6-23
15. Haning H., Niewohner U., and Bischoff E. Phosphodiesterase type 5 (PDE5) inhibitors. Prog Med Chem 41 (2003) 249-306
16. Kloner R.A., Hutter A.M., Emmick J.T., et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 42 (2003) 1855-1860
17. Cheitlin M.D., Hutter Jr. A.M., Brindis R.G., et al. American College of Cardiology/American Heart Association: ACC/AHA expert consensus document: use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 33 (1999) 273-282
18. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 96 (2005) 313-321
19. Kloner R.A., Jackson G., Emmick J.T., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 172 (2004) 1935-1940
20. Emmick J.T., Stuewe S.R., and Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J 4 (2002) H37-H47
21. Lowe F.C. Role of the newer alpha-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 26 (2004) 1701-1713
22. Nordling J. Efficacy and safety of two doses (10 mg and 15 mg) of alfuzosin once daily in the treatment of symptomatic benign prostatic hyperplasia. a double-blind, placebo-controlled, non-comparative active-group study. BJU Int 95 (2005) 1006-1013
23. AUA Practice Guideline Committee. AUA guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
24. Lepor H., and Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia. placebo-controlled, double-blind extension of phase III trial. Urology 51 (1998) 901-906
25. van Moorselaar R.J.A., Hartung R., Emberton M., et al., ALFONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with LUTS and concomitant sexual dysfunction. BJU 95 (2005) 603-608